Introduction of our original chronic liver disease model mouse
We would like to introduce today the world’s first mouse model that induces liver cancer from nonalcoholic steatohepatitis (NASH) – the STAM™ model – developed by SMC Laboratories, Inc.
The model, with a late-onset type 2 diabetic background, has the following advantages compared with other NASH models.
This NASH model;
- reproduces the phenotype of human NASH with mild elevation of ALT, pericentral fibrosis and hepatocyte ballooning
- shows quick onset of disease development to liver cancer by 20 wks of age
- has customizable treatment periods depending on the MOA of the drug or the disease target by virtue of 100% progression to NASH, fibrosis and liver cancer without exception
- has been utilized in collaborations with more than 700 clients/compounds worldwide
- has generated data for 15 compounds that have progressed into P2/P3 clinical trials
- has established positive control (Steatosis / NASH / fibrosis).
[1] Fujii M et al, Med. Mol. Morphol, 2013
[2] Van der Schueren B et al, Int. J. Obes, 2015
[3] Asqharpour A., et al, J. Hepatol., 2016
[4] Clapper JR et al, Am. J. Physiol. Gastrointest. Liver Physiol, 2013
[5] Hansen HH et al, Drug Discov Today, 2017
[6] Van Herck MA et al, Nutrients, 2017
-; none reported
MCD：methionine/choline deficient diets
Recently, a comprehensive analysis of transcriptomics and lipidomics from domestic and international academia has demonstrated the high clinical correlation of this unique model.
More than just a model, we are able to provide optimal drug efficacy evaluation studies in accordance with our clients’ requirements, using our expertise in the field of NASH.